Radiology researcher wins big for work on AI, cardiovascular risk

Chun Yuan, PhD, has received a two-year, $200,000 grant from the American Heart Association’s Institute for Precision Cardiovascular Medicine for his work on using AI to detect blocked arteries and cardiovascular risk. Yuan, a professor of radiology and bioengineering from the University of Washington in Seattle, was also awarded $10,000 in prize money and an additional $50,000 in Amazon Web Service (AWS) service credits to help expand his research going forward.

The research was completed through the American Heart Association’s AWS-powered Precision Medicine Platform. Its focus was the value AI algorithms can provide by assessing knee MRI scans. Yuan found that AI could read MRI scans in a matter of minutes, identifying key features without any help from a human specialist.  

“The especially exciting thing about this research is that we are able to use our technology to detect diseased blood vessels in knee images that were not acquired with that in mind,” Yuan said in a prepared statement.

“These awards are designed to inspire the brightest minds in computer science,” Jennifer Hall, PhD, chief of the Institute for Precision Cardiovascular Medicine, said in the same statement. “By offering researchers like Dr. Yuan secure workspaces and new tools for data analysis, we aim to drive fresh approaches to improve precision medicine.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.